Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hardman & Co
Despite generating a fairly regular flow of news, AstraZeneca (AZN) underperformed the UK index for the first time in several years. It had some disappointments in its R&D pipeline and some of its more recently launched drugs have not seen the expected growth rates given their strong early commercial uptake seen in 2022.
Noveck ...no problem, I was playing at being pedantic.
Ref' AZN sp....I hope you're wrong but, like many, I'm very
p€€d off at the ftse performance overall. Investing culture on a big downward trend in this depressing, demoralising country and not much sign of any improvement....no matter who 'governs ' us. Good luck to us all in every aspect of our lives and my grandkids future.
Good point well made Yam..
£120+ to £80 something, my bad.
Still not cheap and will get cheaper - time will tell innit...
Noveck.... being as you like to be "accurate " why do you say £12 ? Surely you meant £120. D!{k. LOL
I just see this being range bound for a while…..buy below 100, sell at 110. (Obviously NFG will set these bounds lower - each top their own).
Grayling, you're a yappy, clueless keyboard warrior PR1(CK).
I'm a little more accurate in my prediction of a downtrend on this overvalued nonsense than you've been.
I said it would drop significantly when it was over £12 share, and it's massively underperformed the market since. It's now less than 10% from having an 8 in front of the share price as I said it would..
Empty vessels make the most noise..!
And precisely which company do you think would make the largest takeover ever by bidding for AZN?
I do not recall the Share price rocketing on the back of COVID, if anything it did the opposite, the price started rising once COVID was over and everything started getting back to normal.
Yes I hold astra shares but unfortunately anything with plc at the end takes a beating if there's any disappointment to latch onto...
Mr Market thinks otherwise. Number crunching overnight will result in more movements tomorrow. Which way is anyone's guess.
Pretty good financial report overall from Astrazeneca. The future prospects look good with the oncology side of the business absolutely flying.
Russ. Seems daft to me but this share is a long term hold.
Does £6.50?
That clown Noveckingood will be back soon telling us that AZN is grossly overvalued and he will be back in when it drops into the 800’s. LOL
Entirely predictable given the current febrile market and they did miss their target. It will settle back down and at least the reason for some of the lower profits was increased R&D expenditure ie. Reinvesting profits for future growth.
Bit annoying to see the lack of dividend growth - but not been through the results in detail
Annual results really warrant a drop of over £ 2.50 a share ?
I remember when these boards were awash with indignation at government intervention aimed at discouraging AZN institutional shareholders from backing the Pfizer takeover bid at £55 per share. Let the market work it's magic they said, take the money and run etc. ad nauseum. Well what a difference there is now. Pfizer down 60% from its Covid vaccine highs and now a recovery play. Meanwhile AZN (which virtually gave away it's Covid19 vaccine at cost) is sitting stable at almost double the bid price and with it's oncology pipeline the envy of others. LOL
Not sure if the movements up and down between 102-108 is a sign of lost direction over last 6months.
Remember this SP rocketed on back of COVID, just like ROG.SW.
I think this has been a sell for last month or two.
There is good NEWS, but it’s not news we need its results and gains from this.
There is one out of 12 brokers that has a £134 target, others £100-£108.
If you have a look further afield there are better options that will outperform this bluechip.
Don’t just invest solely in UK chips…
GLA
Astrazeneca is looking more like a Takeover target by the day.
Apparently because AZN is uniquely vulnerable to the lower drug price ceilings introduced by Biden’s Inflation Reduction Act? Why on earth this should be the case is beyond me. Go figure, LOL
Odd that UBS has reduced price target and Morgan Stanley has raised it. Market seems to be listening to UBS!
Times mention, for what it’s worth:
https://www.thetimes.co.uk/article/b75077c7-c28c-4a6b-afcf-cb978ed28d3d
Looking back one year later, I could buy back last slice 9% cheaper now .
Did not sell at the top either which was 12,294 on 24/4/23.
The low one month ago 9,900 on 29/11/23.
BARRON'S ( whoever they are say good buy now )
BIOTECH AND PHARMA
BARRON'S STOCK PICK
Buy AstraZeneca Stock. It Looks Much Better Going Into 2024.
By Teresa Rivas Dec 28, 2023
Big pharmaceutical companies create the medications that keep countless people around the world healthy, but that hasn’t helped their ailing stock prices this year. The United Kingdom-based AstraZeneca has been no exception, but its shares could get a shot in the arm in 2024.
Nirsevimab the successful new vaccine for babies to prevent pneumonia has just been rolled out in the US and Spain. Produced by Sanofi and AZN. Should boost the SP.